A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands:The Dutch Multiple Sclerosis Study protocol by Jongen, Peter Joseph et al.
  
 University of Groningen
A prospective web-based patient-centred interactive study of long-term disabilities, disabilities
perception and health-related quality of life in patients with multiple sclerosis in The
Netherlands
Jongen, Peter Joseph; Heerings, Marco; Lemmens, Wim A.; Donders, Rogier; van der Zande,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Jongen, P. J., Heerings, M., Lemmens, W. A., Donders, R., van der Zande, A., van Noort, E., & Kool, A.
(2015). A prospective web-based patient-centred interactive study of long-term disabilities, disabilities
perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: The Dutch
Multiple Sclerosis Study protocol. BMC NEUROLOGY, 15(128), [128]. https://doi.org/10.1186/s12883-015-
0379-0
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
STUDY PROTOCOL Open Access
A prospective web-based patient-centred
interactive study of long-term disabilities,
disabilities perception and health-related
quality of life in patients with multiple
sclerosis in The Netherlands: the Dutch
Multiple Sclerosis Study protocol
Peter Joseph Jongen1,2*, Marco Heerings3,4, Wim A. Lemmens5, Rogier Donders5, Anneke van der Zande4,
Esther van Noort6 and Anton Kool6
Abstract
Background: In the past two decades the widespread use of disease modifying drugs with moderate to strong
efficacy has changed the natural course of multiple sclerosis (MS). Health care professionals, researchers, patient
organizations and health authorities are in need of recent information about the objectified and subjective
long-term clinical outcomes in MS patients. Such information is scarce.
Methods/Design: We started a prospective, web-based, patient-centred, interactive study of long-term
disabilities, disabilities perception and health-related quality of life (HRQoL) in MS patients in The Netherlands
(Dutch Multiple Sclerosis Study). The study has an on online patient-driven inclusion and online acquisition of
patient-reported outcomes (PROs). At six-months intervals participants complete the Multiple Sclerosis Impact
Profile (MSIP) (disabilities and disabilities perception in seven domains and four symptoms), the Multiple
Sclerosis Quality of Life-54 items (MSQoL-54), the Modified Fatigue Impact Scale-5 items (MFIS-5) and the Leeds
Multiple Sclerosis Quality of Life-8 items (LMSQoL) questionnaires, and a Medication and Adherence Inventory.
Every three years the Expanded Disability Status Scale (EDSS) score is assessed by phone. The monthly completion of
the MFIS-5, LMSQoL and Medication and Adherence Inventory is optional. Completed questionnaires and inventories,
and automatically generated scores are made available online to patients for self-monitoring and self-management
purposes, and to authorized health care professionals for the evaluation of disease activity and of the effectiveness of
treatments. Study duration is planned to be 15 years. Results will be analyzed periodically using means and standard
deviations for continuous variables, and frequencies for categorical variables. Relations between time points, variables,
patient and treatment characteristics will be evaluated in random effects repeated measures models.
(Continued on next page)
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Discussion: The Dutch Multiple Sclerosis Study is characterized by online patient-driven inclusion; online data
acquisition; the use of PROs; the optional monthly completion of short questionnaires; the interactive use of
personal study data by patients and authorized health care professionals for self-monitoring, self-management and
multidisciplinary care; the expected representativeness of the study sample; and a long-term time horizon. The
study will provide valuable data on long-term disabilities, disabilities perceptions and HRQoL in MS patients in
The Netherlands.
Keywords: Multiple sclerosis, Clinically isolated syndrome, Long-term, Disability, Quality of life, Patient-driven,
Patient-centred, Patient-reported outcomes, Web-based, Online
Background
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system, pathologically characterized by
immune-mediated inflammation, demyelination and
axonal degeneration. In most patients the initial disease
course is characterised by relapses and remissions:
relapsing remitting MS (RRMS) [1]. After a first epi-
sode patients may be diagnosed with Clinically
Isolated Syndrome (CIS) suggestive of MS [1]. In CIS
and RRMS immune activity and inflammation are the
major underlying processes. Due to recurrent relapses
and incomplete remissions RRMS patients often ex-
perience a step-wise increase in disability [1]. Since
about two decades the number and severity of re-
lapses can be reduced by treatment with immunomo-
dulating or immunosuppressive disease modifying
drugs (DMDs), as a result of which further increase
in disability may be slowed or stopped [2, 3]. Long-
term treatment with potent DMDs may even lead to
an improvement of neurological functions [4].
After approximately 10–15 years most patients with
RRMS convert to the Secondary Progressive (SP) phase,
that is characterized by a slow and relentless increase in
disability and a virtual absence of relapses [1]. DMDs
have been reported to delay the conversion to SPMS and
also to slow down the rate of progression once the SP
phase has started [5–9]. In about 10-15 % of MS patients
symptoms start and develop slowly without relapses:
Primary Progressive MS (PPMS). In both SPMS and
PPMS the continuous increase in disability is thought
to result from degenerative processes and the disease
course cannot be modified by treatment with the
available DMDs.
MS profoundly diminishes health-related quality of
life (HRQoL) due to the fact that symptoms often
interfere with physical, cognitive, social or occupa-
tional activities [10]. A primary determinant of
impaired HRQoL in MS is fatigue [11], occurring
in over 80 % of patients [12]. It has been reported
that DMD treatment may improve MS-related
fatigue, but long-lasting benefits have not been
documented [13].
Prospective long-term studies on disabilities and
HRQoL in treated and untreated MS and CIS pa-
tients in real life settings are scarce. Such studies
have been performed in the U.S.A., Canada, France
and Italy [6, 7, 14–18], but they either date from the
pre-DMD era, were restricted to specific regions or
mainly involved patients treated in academic centres.
Consequently, the findings are not applicable to the
present MS population or cannot readily be general-
ized to patients in other countries or to those treated
in general practices. As far as Dutch studies are con-
cerned, Zwanikken in his thesis provided a detailed
evaluation of the epidemiology, disability and HRQoL
in Dutch MS patients [19]. However, these data were
obtained in the era before the availability of DMDs
and in the northern provinces only. To our know-
ledge recent data on long-term clinical changes in
MS patients are not available in The Netherlands.
In a study on the costs of MS in the Netherlands it
was found that the total mean costs per patient are
driven essentially by the severity level, increasing from
euro 9,300 per year at Expanded Disability Status Scale
(EDSS) scores of 0–1 to euro 78,000 per year at EDSS
scores of 8–9 [20]. The costs related to a relapse vary
from approximately euro 50 to euro 9,000, depending on
the relapse intensity [21]. Against this background of
economic consequences of MS, it is important to be in-
formed about the long-term changes in disability levels
in MS patients [22]. Moreover, given the budgets restric-
tions to the Dutch health care system, the allocation of
resources for MS care, both on macro-, meso- and
micro-levels, should conceivably also be guided by the
priority given by patients themselves to the various
symptoms. Thus, patients’ perception of disability-
related problems may help health care professionals to
prioritize their care according to the subjective relevance
of disabilities. HRQoL is an overall measure of wellbeing
from a patient’s perspective and, as a patient-reported
outcome (PRO), it can easily be assessed without in-
volvement of neurologist or MS nurse, and yet providing
a comprehensive measure of health status [8–10].
HRQoL is increasingly becoming an important measure
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in the assessment of disease burden in MS and in the
evaluation of the effectiveness of DMD treatment [23, 24].
In view of the above, the availability of prospectively
acquired data about the long-term changes in disability,
disability perception and HRQoL in MS patients in the
Netherlands will entail various significant advantages. In
RRMS patients, long-term data will enable the evalu-
ation of the effectiveness and therapeutic value of DMD
treatment and thus establish a new natural history of the
disease [6]; in SPMS and PPMS patients, information on
long-term changes provides a point of reference for the
real-life effectiveness of future DMD treatments. More-
over, long-term data on disability perception and HRQoL
could be relevant to the comprehensive assessment of
present and future needs of MS patients in terms of multi-
disciplinary care. This information may also be useful for
MS patient organisations, looking after the interests of
their members, e.g. in their communications with health
insurers, and to health authorities, seeking guidance for
policy decisions. For these various reasons we conceived
and started the Dutch Multiple Sclerosis Study.
Methods/Design
Study objectives
The primary study objectives are to assess in patients with
MS the long-term changes in 1) disabilities, 2) disabilities
perception and 3) HRQoL. The secondary objectives are to
assess the interrelations between 1) changes in disabilities
and changes in disabilities perceptions, 2) changes in dis-
abilities and changes in HRQoL, 3) relapses and changes in
disabilities, 4) (adherence to) DMD treatment and changes
in disabilities, and 5) (adherence to) DMD treatment and
change in fatigue.
Study design
The Dutch Multiple Sclerosis Study is a prospective, web-
based, patient-centred, longitudinal, observational study in
The Netherlands, with patient-driven inclusion. Given the
innovative character of the study concept initially a follow-
up of 2 years was planned to assess the feasibility of the
project. Since then the study has been extended annually
and is now expected to have a follow-up of 15 years.
Study population
The population under study are the MS and CIS patients
in The Netherlands. Accordingly, the eligibility criteria
for patients to participate were not restrictive: 1) diagno-
sis of MS or CIS, 2) willing and able to comply with
the study protocol, 3) having access to the internet, and
4) having given informed consent.
Patient recruitment
Patients were informed on the possibility to participate
via the websites of the patient organisations National
MS Foundation The Netherlands (NMSF) (www.nmsf.nl)
and Multiple Sclerose Vereniging Nederland (MSVN)
(www.msweb.nl), the website of the MS4 Research
Institute (www.ms4ri.nl), the study website www.
msstudie.nl. By regular mail neurologists and MS-
nurses in The Netherlands were sent an informative
letter with patient brochures, which they were asked
to hand out to their patients. The brochure was also
sent to the patrons of the NMSF as an attachment to
the foundations’ quarterly journal and related mail-
ings. In the journal, study information was presented
by the principal investigator (PJJ). Twice information
about the study was published in health specials of
large national and regional Dutch newspapers.
The informed consent text was available on
www.msstudie.nl en www.ms4ri.nl. For further infor-
mation the principal investigator (PJJ) could be con-
tacted via www.ms4ri.nl. Patients who were willing to
participate confirmed that they had read the information
and gave their informed consent online by clicking on a
specific page of the study website. The electronic consent
also pertained the storage of personal data and the re-
sponses in the database. Once informed consent was ob-
tained, a patient could start the baseline assessment.
Ethical aspects
The protocol was submitted to the ethics committee
Medisch Ethische Toetsing Onderzoek Patiënten en
Proefpersonen in Tilburg, The Netherlands (nr M379).
The committee concluded that a review was not indi-
cated, as the study did not qualify for being tested ac-
cording to the Dutch Medical Research Involving
Human Subjects Act of 1999 (http://wetten.overheid.nl/
BWBR0009408) [25]. The study is being performed in
agreement with the Declaration of Helsinki (Ethical
Principles for Medical Research Involving Human Subjects
version 2013; 64th World Medical Association General
Assembly, Fortaleza, Brazil, October 2013) (www.wma.net)
and the Wet medisch-wetenschappelijk onderzoek met
mensen (www.wetten.overheid.nl/BWBR0009408). The
data analyses plan will be checked by an independent
supervisory board (Stichting Infometer). Patients were
informed that they have the right to discontinue their
participation or withdraw their consent at any time and
are not obliged to state their reasons. The completion
of the questionnaires takes about 30–45 min every six
months; the optional completion of the monthly ques-
tionnaires takes about 15 min every month; every three
years the assessment of the EDSS by phone takes about
10 to 20 min (see below).
Data acquisition
After having given their consent, patients received a per-
sonal code and logged on to the website of the study
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www.msstudie.nl, to choose a username and password.
Online they go through various web pages containing
the electronic case record forms (e-CRFs) with questions
and questionnaires. Patients are informed by e-mail that
an assessment is due and that the corresponding e-CRFs
have been made available for completion. E-CRFs are to
be completed within one week. Within this time frame
e-CRFs may be filled in at moments that are suitable to
the patient. Completion may take as many sessions as
needed, as answers are saved automatically. The items of
the questionnaire are fixed and the responses are auto-
matically captured. Automated completeness checks are
done before questionnaires can be submitted. The re-
spondents see an overview of all questions and answers
before submission and they can change the answers be-
fore submitting. After confirmation the e-CRF is auto-
matically sent to the study centre. After submission
changes are no longer possible. In case a e-CRF has not
been completed within one week the help desk sends a
reminder by e-mail.
Technical aspects
The study is a modular application on the Curavista
e-Health Platform, built on an Oracle database with
JAVA-scripting, XML-applets and AJAX protocols. Data
processing is 256-bits encrypted with VPN-tunnelling.
The databases are physically and software secured in a
dedicated data centre in The Netherlands. The database
of the study is compliant with EU-regulations on data
storage and activation for medical purposes. There are
four separated databases: one with personal identifiers
(name, address, identification number), one with medical
records (answers to the questions, identification number),
one with the social security number, and one with the key.
Only after login the data are presented as a whole on the
screen (encrypted key).
Outcome measures
Disabilities and disabilities perception
The EDSS is a widely used disability measure in MS.
The EDSS quantifies disability in eight functional sys-
tems and allows neurologists to assign a functional sys-
tem score in each of these [26]. The functional systems
are: pyramidal, cerebellar, brainstem, sensory, bowel and
bladder, visual, cerebral and other. EDSS steps 1.0 to 4.5
refer to patients with MS who are fully ambulatory, and
EDSS steps 5.0 to 9.5 are defined by the impairment to
ambulation. A version of the EDSS that can be used by
phone is available and will be used in this study [27].
The MSIP is a measure of MS-related disabilities and
perception of disabilities with established psychomet-
ric properties [28, 29]. The MSIP is based on the
International Classification of Functioning, Disability and
Health and reflects an objectified view of the prevalence
and severity of the impact of MS. The MSIP comprises 36
questions assessing disability (Q1a-Q36a) and disability
perception (Q1b-Q36b) in the domains Muscle and
Movement Functions (MMF), Excretion and Reproductive
Functions (ERF), Basic Movement Activities (BMA),
Activities of Daily Living (ADL), Participation in Life
Situations (PLS), Environmental Factors (EF), Mental
Functions (MF), and the symptoms fatigue, pain, speech
and vision. The MSIP yields validated domain scores, ran-
ging from 0 to 12 (ERF, MF), 0 to 15 (BMA), 0 to 16
(MMF), 0 to 20 (EF), 0 to 24 (ADL), and 0 to 26 (PLS), and
symptom scores, ranging from 0 to 4. Higher scores indi-
cate a worse condition.
HRQoL
HRQoL is assessed with the MSQoL-54 and the
LMSQoL questionnaires. The MSQoL-54 is a psycho-
metrically validated MS-specific multi-dimensional in-
ventory of patient-centered health status [13]. It consists
of the 36-item Short Form health survey as a generic
core measure to enable comparisons to other patient
populations and to the general population, supple-
mented with 18 additional questions exploring items
relevant to patients with MS in the areas of health dis-
tress (four items), sexual function (four items), satisfac-
tion with sexual function (one item), overall quality of
life (two items), cognitive function (four items), energy
(one item), pain (one item) and social function (one
item) [30]. The MSQoL-54 contains 52 items distributed
into 12 scales, and two single items. A physical and a
mental dimension underlie the MSQoL-54: the physical
and mental domains. Scores for each domain range from
0 to 100, where higher values indicate better HRQoL.
The Leeds Multiple Sclerosis Quality of Life (LMSQoL)
questionnaire is a psychometrically validated scale that
consists of eight questions, examining MS-related as-
pects of QoL over the past month [31]. Answers are
rated on a 5-point scale from 0 to 4. The resulting
score ranges from 8 to 32, with higher scores reflecting
higher levels of well being. In a study of MS patients
with acute relapses, it was found to be responsive to
change with higher effect sizes than the sub-scales of
the MSQoL-54, and it also showed a correlation with a
detailed impact diary [32].
Relapses
Patients report the occurrence of relapses, the relapse
intensity and eventual steroid treatment over the past
six months.
Medication and adherence to DMD
The Medication and Adherence Inventory gives a
patient-reported update of medications that are taken,
the number of missed doses DMD in the past month
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(if applicable), and the date and reason of DMD dis-
continuation (if applicable).
Fatigue
Fatigue is measured by the Multiple Sclerosis Fatigue
Impact Scale 5-item version (MFIS-5), a validated, short
questionnaire examining a patient’s perceived impact of
fatigue on a variety of daily activities over the past
month [33]. Answers to each question are rated on a
5-point scale from 0 to 4. The MFIS-5 total score
consists of the sum of the raw scores on these 5
items and ranges from 0 to 20, where higher scores
indicate more experienced fatigue.
Assessment schedule
At baseline the MSIP, MSQoL-54, Relapse Report,
Medication and Adherence Inventory and MFIS-5
were completed, and the EDSS score was assessed by
phone (MH). At follow-up the MSIP, MSQoL-54, Re-
lapse Report, Medication and Adherence Inventory
and MFIS-5 are completed every 6 months, and the
EDSS score is assessed every 3 years. The monthly
completion of MFIS-5, LMSQoL and Medication and
Adherence Inventory is optional.
Statistical analyses
The statistical analyses will be performed at the
Department for Health Evidence, University Medical
Centre Radboud Nijmegen, The Netherlands. Results
will be described using means and standard deviations
for continuous variables, and frequencies for categorical
variables. Relations between time points, variables, pa-
tient and treatment characteristics will be evaluated in
random effects repeated measures models. Multi-variate
analyses will be performed to examine the interrelations
described under the section Ojectives.
Study status
A total of 391 patients have been included, the first patient
in May 2011 and the last patient in September 2012.
Organisation and funding
The study is an initiative of MS4 Research Institute (PJJ),
and carried out by the institute in collaboration with
Curavista bv. The study’s Advisory Committee includes
Prof. Raymond Hupperts, neurologist, Academic MS
Centre Limburg, Sittard, The Netherlands, Dr. Freek
Verheul, neurologist, Groene Hart Hospital Gouda,
Gouda, The Netherlands, Dr. Thea Heersema, University
Medical Centre Groningen, Groningen, The Netherlands,
and Dr. Ruud van der Kruijk, neurologist, Slingeland
Hospital Doetinchem, Doetinchem, The Netherlands.
The study is funded by the National MS Foundation The
Netherlands, Curavista bv and MS4 Research Institute.
Discussion
The Dutch Multiple Sclerosis Study is a prospective,
web-based, patient-centred study of long-term disability,
disability perception and HRQol in patients with MS in
The Netherlands. The study has several distinguishing
features. First, the web-based character: potential partici-
pants were informed via a downloadable patient infor-
mation form, applied for participation via the study
website, and approved online the informed consent
form. Second, the study is patient-centred with a
patient-driven inclusion, as all outcomes are PROs and
patients included themselves online, whereas usually
studies focus on doctor-reported data, and neurologists
and nurses are instrumental in the selection and inclu-
sion of patients. In fact, we established a research part-
nership with patients without formal selection by health
care professionals. As to the PROs, given the intrinsic
clinical relevance of PRO-based conclusions, the imple-
mentation of the study results into clinical practice or
their utilization for policy decisions is without concep-
tual barriers. Third, the study is interactive in that the
personal study data are made available online to the pa-
tient in tables and graphs and can be used for self-
monitoring purposes. Patients may also authorize their
neurologist, MS-nurse and other health care profes-
sionals online access to the completed questionnaires
and scores. This information can be used by the patient’s
caregivers. Thus, the MSIP provides a comprehensive
overview of disabilities and disabilities perceptions, and
the visual representation of the scores with colour codes
facilitates the detection of worsening compared to the
last visit; the MSQoL-54 score may help in the assess-
ment of clinical disease activity from the patient’s per-
spective and in the evaluation of DMD treatment. The
optional monthly use of the MFIS-5, LMSQoL and
Medication and Adherence Inventory may contribute to
the self-management of fatigue, and to the professional
evaluation of symptomatic treatments. Notably, in those
neurological practices where the standard performance
of EDSS scoring is not feasible, the PROs generated in
the study may provide valuable information. In all, it is
thought that the interactive use of study data may
improve the efficiency and quality of professional multi-
disciplinary care and facilitate self-management. The
feedback of completed questionnaires, scores and inven-
tories, and their utilization by health care professionals
and patients (self-monitoring, self-management) is be-
lieved to add practical value to the study participation
and may constitute an incentive to continue participa-
tion. Especially in long-term studies the prevention of
drop-outs is important. Fourth, as patients were in-
formed all over the country, irrespective of their place of
residency or treatment setting (general neurologist or
MS-specialised neurologist; academic centre or general
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hospital), the study population is likely to be representa-
tive of the MS patients living in the Netherlands. This
will increase the external validity of the study results.
Conclusions
The Dutch Multiple Sclerosis Study is a prospective,
web-based, patient-centred, interactive, study of long-
term disabilities, disabilities perception and HRQoL in
patients with MS in the Netherlands. The innovative
study design is characterized by online patient-driven in-
clusion; online data acquisition; the use of PROs; the op-
tional frequent completion of short questionnaires; the
interactive use of personal study data by patients and au-
thorized health care professionals for self-monitoring,
self-management and multidisciplinary care; the ex-
pected representativeness of the study sample; and the
long-term time horizon. The study will provide valuable
reference data on long-term disabilities, disabilities percep-
tions and HRQoL in MS patients in The Netherlands.
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